N/A
Completed N=453
Evaluation of the LDL-C Lowering Effects of Ezetimibe Achieved in Co-administration Therapy With Statins in an Indonesian Population (Study P04276)(COMPLETED)
Source: ClinicalTrials.gov NCT00705081 ↗Enrolled (actual)
453
Serious AEs
0.0%
Results posted
Aug 2009
Primary outcomePrimary: Number of Participants Reporting Adverse Events — 1; 1 Participants
Summary
The purpose of this study is to evaluate the safety and tolerability of the low-density lipoprotein-cholesterol (LDL-C) lowering in an Indonesian population treated with ezetimibe co-administered with a statin in routine daily practice. In addition, the study will investigate whether and to what extent the target levels set by the participating doctors are achieved by the co-administration therapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Reporting Adverse Events |
1; 1 | — |
| PRIMARY Intensity of Adverse Events Reported |
1; 1; 0; 0; 0; 0 | — |
| PRIMARY Participants Achieving Low-density Lipoprotein-cholesterol (LDL-C) Target Levels With Co-administration Therapy |
101; 106 | — |
Eligibility Criteria
Inclusion Criteria
- All subjects that were to receive ezetimibe 10 mg as prescribed in daily practice
Exclusion Criteria
- N/A
Data sourced from ClinicalTrials.gov (NCT00705081). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.